<DOC>
	<DOCNO>NCT02501278</DOCNO>
	<brief_summary>The aim study assess potential benefit addition immunotherapy VGX-3100 INO-9012 ( i.e . INO-3112 ) concomitant CRT , concomitant CRT continue adjuvant patient locally advanced cervical cancer . Safety run-in : To test safety CRT combine immunotherapy INO-3112 . This safety run-in phase include first 3 patient treat two INO-3112 combination arm expose least two immunotherapy dos evaluate whether combination pose undue immediate risk patient enrol trial . Phase II : To demonstrate sufficient activity experimental combination arm warrant phase III conclusive trial base progression free survival ( PFS ) 18 month assess RECIST local investigator . The efficacy assess within experimental arm standard arm serve reference arm check reliability result .</brief_summary>
	<brief_title>A Phase II Clinical Trial Chemo-radiotherapy Combination With INO-3112 Patients With Locally Advanced Cervical Cancer</brief_title>
	<detailed_description />
	<mesh_term>Uterine Cervical Neoplasms</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>Main inclusion criterion : Registration step Age 18 year old ; Newly diagnose locally advanced cervical cancer define FIGO 2009 : stage IB2 , IIA &amp; IIB , IIIA &amp; IIIB IVA disease ; No evidence distant metastasis ( Stage IVB ) ; Histological diagnosis squamous cell carcinoma , adenocarcinoma adenosquamous cell carcinoma cervix accept . Not accept small cell , clear cell rare variant classical adenocarcinoma ; Availability HPV 16 HPV 18 testing ; No HIV seropositive , Hepatitis B C ( unless sustain virologic response achieve antiHCV therapy ) ; Written inform consent must give accord ICH/GCP , national/local regulation Randomization step Positive HPV 16 and/or HPV 18 assess central lab ; WHO/ECOG performance status 0 2 Adequate hematological , liver renal function ECG clinically significant finding assess investigator perform within 30 day sign informed consent form Absence current malignancy site , exception adequately treat basal squamous cell carcinoma skin . Cancer survivor , undergone potentially curative therapy prior malignancy , evidence disease five year deem low risk recurrence , eligible study ; No prior history clinically significant autoimmune disease , Crohn 's disease , ulcerative colitis ; No history previous therapeutic HPV vaccination ( individual immunize license prophylactic HPV vaccine ( e.g . Silgard® , Cervarix® , Gardasil® ) exclude ) ; No know suspect hypersensitivity component ( ) investigational product cisplatin contraindication ( e.g . peripheral neuropathy ≤ grade 2 ototoxicity ≤ grade 2 per CTCAE v4 ) ; No previous pelvic RT ; No previous chemotherapy tumor ; No patient undergone previous hysterectomy hysterectomy part initial cervical cancer therapy ; No receipt immunotherapy within 4 week start protocol treatment ; No prior major surgery within 4 week randomization patient recover .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>